Skip to main content

Advertisement

SpringerLink
Log in

Use of bisphosphonates in multiple myeloma patients in Denmark, 2005–2015

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

To describe use of bisphosphonates in newly diagnosed multiple myeloma patients in Denmark.

Methods

Using data from the Danish National Multiple Myeloma Registry, we conducted a population-based cohort study. Among patients newly diagnosed with multiple myeloma from 2005 to 2015, we examined use of bisphosphonates at first- and at progression/second-line anti-myeloma treatment overall, by patient characteristics, and myeloma complications.

Results

Of 2947 patients starting first-line anti-myeloma treatment, 2207 patients (74.9%) received bisphosphonates. During a median follow-up of 27.6 (quartiles, 10.6–52.5) months, disease progression post-first-line treatment was recorded in 1546 patients, of whom 1065 (68.9%) were treated with bisphosphonates. Altogether, 80.9% of patients with and 37.6% of patients without myeloma bone disease were treated with bisphosphonates at first line and 73.0% and 42.7%, respectively, at progression/second line. Moreover, the proportion of patients treated with bisphosphonates decreased with increasing severity of renal impairment at first and at progression/second-line treatment.

Conclusion

The proportion of patients treated with bisphosphonates as part of first- and second-line anti-myeloma treatment increased with presence of myeloma bone disease and decreased by presence and severity of renal impairment. Overall, 25% of newly diagnosed multiple myeloma patients had no record of bisphosphonate treatment, potentially indicating an unmet need.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data availability

The manuscript has no associated data or the data will not be deposited.

References

  1. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538–e548. https://doi.org/10.1016/s1470-2045(14)70442-5

    Article  PubMed  Google Scholar 

  2. NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic countries, Version 8.2 (26.03.2019). Association of the Nordic Cancer Registries. Danish Cancer Society. Available from: http://www.ancr.nu. Accessed 5 April 2019

  3. Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H (2014) IMWG consensus on risk stratification in multiple myeloma. Leukemia 28(2):269–277. https://doi.org/10.1038/leu.2013.247

    Article  CAS  PubMed  Google Scholar 

  4. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28(5):1122–1128. https://doi.org/10.1038/leu.2013.313

    Article  CAS  PubMed  Google Scholar 

  5. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5):2516–2520. https://doi.org/10.1182/blood-2007-10-116129

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78(1):21–33. https://doi.org/10.4065/78.1.21

    Article  PubMed  Google Scholar 

  7. Rasch S, Lund T, Asmussen JT, Lerberg Nielsen A, Faebo Larsen R, Østerheden Andersen M, Abildgaard N (2020) Multiple myeloma associated bone disease. Cancers (Basel) 12(8). https://doi.org/10.3390/cancers12082113

  8. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, Michaeli J, Epstein J, Choi Y (2001) Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 98(20):11581–11586. https://doi.org/10.1073/pnas.201394498

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349(26):2483–2494. https://doi.org/10.1056/NEJMoa030847

    Article  CAS  PubMed  Google Scholar 

  10. Bataille R, Chappard D, Marcelli C, Dessauw P, Sany J, Baldet P, Alexandre C (1989) Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 7(12):1909–1914. https://doi.org/10.1200/jco.1989.7.12.1909

    Article  CAS  PubMed  Google Scholar 

  11. Rogers MJ, Crockett JC, Coxon FP, Monkkonen J (2011) Biochemical and molecular mechanisms of action of bisphosphonates. Bone 49(1):34–41. https://doi.org/10.1016/j.bone.2010.11.008

    Article  CAS  PubMed  Google Scholar 

  12. Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B (2017) Bisphosphonates in multiple myeloma: an updated network meta-analysis. Cochrane Database Syst Rev 12:Cd003188. https://doi.org/10.1002/14651858.CD003188.pub4

    Article  PubMed  Google Scholar 

  13. Rollig C, Knop S, Bornhauser M (2015) Multiple myeloma. Lancet 385(9983):2197–2208. https://doi.org/10.1016/s0140-6736(14)60493-1

    Article  PubMed  Google Scholar 

  14. Morgan GJ, Child JA, Gregory WM, Szubert AJ, Cocks K, Bell SE, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross FM, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Wu P, Davies FE, National Cancer Research Institute Haematological Oncology Clinical Studies G (2011) Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol 12(8):743–752. https://doi.org/10.1016/S1470-2045(11)70157-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7(5):377–387

    CAS  PubMed  Google Scholar 

  16. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J, Knight RD (1998) Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16(2):593–602. https://doi.org/10.1200/jco.1998.16.2.593

    Article  CAS  PubMed  Google Scholar 

  17. Gimsing P, Carlson K, Turesson I, Fayers P, Waage A, Vangsted A, Mylin A, Gluud C, Juliusson G, Gregersen H, Hjorth-Hansen H, Nesthus I, Dahl IM, Westin J, Nielsen JL, Knudsen LM, Ahlberg L, Hjorth M, Abildgaard N, Andersen NF, Linder O, Wisloff F (2010) Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. Lancet Oncol 11(10):973–982. https://doi.org/10.1016/s1470-2045(10)70198-4

    Article  CAS  PubMed  Google Scholar 

  18. Terpos E, Morgan G, Dimopoulos MA, Drake MT, Lentzsch S, Raje N, Sezer O, Garcia-Sanz R, Shimizu K, Turesson I, Reiman T, Jurczyszyn A, Merlini G, Spencer A, Leleu X, Cavo M, Munshi N, Rajkumar SV, Durie BG, Roodman GD (2013) International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol 31(18):2347–2357. https://doi.org/10.1200/jco.2012.47.7901

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Dansk Myelomatose Studie Gruppe (DMSG) (2017) Diagnostik og behandling af myelomatose. Retningslinje 2017. Available from: https://myeloma.hematology.dk/index.php/vejledninger-dmsg. Accessed 08/07/2020

  20. Gonsalves WI, Leung N, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Kapoor P, Go RS, Lin Y, Russell SJ, Lust JA, Zeldenrust S, Kyle RA, Gertz MA, Kumar SK (2015) Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J 5:e296. https://doi.org/10.1038/bcj.2015.20

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Raab MS, Cavo M, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, Safaei R, Karlin L, Mateos MV, Schoen P, Yong K (2016) Multiple myeloma: practice patterns across Europe. Br J Haematol 175(1):66–76. https://doi.org/10.1111/bjh.14193

    Article  PubMed  Google Scholar 

  22. Raje N, Terpos E, Willenbacher W, Shimizu K, Garcia-Sanz R, Durie B, Legiec W, Krejci M, Laribi K, Zhu L, Cheng P, Warner D, Roodman GD (2018) Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol 19(3):370–381. https://doi.org/10.1016/s1470-2045(18)30072-x

    Article  CAS  PubMed  Google Scholar 

  23. Gimsing P, Holmstrom MO, Klausen TW, Andersen NF, Gregersen H, Pedersen RS, Plesner T, Pedersen PT, Frederiksen M, Frolund U, Helleberg C, Vangsted A, de Nully BP, Abildgaard N (2016) The Danish National Multiple Myeloma Registry. Clin Epidemiol 8:583–587. https://doi.org/10.2147/clep.S99463

    Article  PubMed  PubMed Central  Google Scholar 

  24. Pedersen CB (2011) The Danish Civil Registration System. Scand J Public Health 39(7 Suppl):22–25. https://doi.org/10.1177/1403494810387965

    Article  PubMed  Google Scholar 

  25. Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT (2015) The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 7:449–490. https://doi.org/10.2147/clep.S91125

    Article  PubMed  PubMed Central  Google Scholar 

  26. Schmidt M, Pedersen L, Sorensen HT (2014) The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 29(8):541–549. https://doi.org/10.1007/s10654-014-9930-3

    Article  PubMed  Google Scholar 

  27. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV (2006) International uniform response criteria for multiple myeloma. Leukemia 20(9):1467–1473. https://doi.org/10.1038/sj.leu.2404284

    Article  CAS  PubMed  Google Scholar 

  28. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139(2):137–147. https://doi.org/10.7326/0003-4819-139-2-200307150-00013

    Article  PubMed  Google Scholar 

  29. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383

    Article  CAS  PubMed  Google Scholar 

  30. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT (2011) The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol 11:83. https://doi.org/10.1186/1471-2288-11-83

    Article  PubMed  PubMed Central  Google Scholar 

  31. Terpos E, Roodman GD, Dimopoulos MA (2013) Optimal use of bisphosphonates in patients with multiple myeloma. Blood 121(17):3325–3328. https://doi.org/10.1182/blood-2012-10-435750

    Article  CAS  PubMed  Google Scholar 

  32. Anderson K, Ismaila N, Flynn PJ, Halabi S, Jagannath S, Ogaily MS, Omel J, Raje N, Roodman GD, Yee GC, Kyle RA (2018) Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 36(8):812–818. https://doi.org/10.1200/jco.2017.76.6402

    Article  CAS  PubMed  Google Scholar 

  33. European Medicines Agency. Xgeva (denosumab). Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/xgeva. Accessed 05/07/2020

  34. Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, Oudard S, Bruland Ø, Flamen P, Kurth A, van Poznak C, Aapro M, Jordan K (2020) Bone health in cancer: ESMO clinical practice guidelines. Ann Oncol 31:1650–1663. https://doi.org/10.1016/j.annonc.2020.07.019

    Article  CAS  PubMed  Google Scholar 

  35. Kajizono M, Sada H, Sugiura Y, Soga Y, Kitamura Y, Matsuoka J, Sendo T (2015) Incidence and risk factors of osteonecrosis of the jaw in advanced cancer patients after treatment with zoledronic acid or denosumab: a retrospective cohort study. Biol Pharm Bull 38(12):1850–1855. https://doi.org/10.1248/bpb.b15-00385

    Article  CAS  PubMed  Google Scholar 

  36. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, Sandor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30(1):3–23. https://doi.org/10.1002/jbmr.2405

    Article  PubMed  Google Scholar 

  37. Khan A, Morrison A, Cheung A, Hashem W, Compston J (2016) Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015. Osteoporos Int 27(3):853–859. https://doi.org/10.1007/s00198-015-3335-3

    Article  CAS  PubMed  Google Scholar 

  38. Mateos MV, Fink L, Koneswaran N, Intorcia M, Giannopoulou C, Niepel D, Cavo M (2020) Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review. BMC Cancer 20(1):170. https://doi.org/10.1186/s12885-020-6596-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, Safaei R, Karlin L, Mateos MV, Raab MS, Schoen P, Cavo M (2016) Multiple myeloma: patient outcomes in real-world practice. Br J Haematol 175(2):252–264. https://doi.org/10.1111/bjh.14213

    Article  PubMed  PubMed Central  Google Scholar 

  40. Leng S, Chen Y, Tsai WY, Bhutani D, Hillyer GC, Lim E, Accordino MK, Wright JD, Hershman DL, Lentzsch S, Neugut AI (2019) Use of bisphosphonates in elderly patients with newly diagnosed multiple myeloma. J Natl Compr Cancer Netw 17(1):22–28. https://doi.org/10.6004/jnccn.2018.7079

    Article  CAS  Google Scholar 

  41. Kim C, Hernandez RK, Cyprien L, Liede A, Cheng PC (2018) Patterns of bisphosphonate treatment among patients with multiple myeloma treated at oncology clinics across the USA: observations from real-world data. Support Care Cancer 26(8):2833–2841. https://doi.org/10.1007/s00520-018-4133-1

    Article  PubMed  PubMed Central  Google Scholar 

  42. Garcia-Sanz R, Oriol A, Moreno MJ, de la Rubia J, Payer AR, Hernandez MT, Palomera L, Teruel AI, Blanchard MJ, Gironella M, Ribas P, Bargay J, Abella E, Granell M, Ocio EM, Ribera JM, San Miguel JF, Mateos MV (2015) Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial. Haematologica 100(9):1207–1213. https://doi.org/10.3324/haematol.2015.128439

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Sanfilippo KM, Gage B, Luo S, Weilbaecher K, Tomasson M, Vij R, Colditz G, Carson K (2015) Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma. Leuk Lymphoma 56(3):615–621. https://doi.org/10.3109/10428194.2014.924117

    Article  CAS  PubMed  Google Scholar 

  44. Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA (2010) First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376(9757):1989–1999. https://doi.org/10.1016/s0140-6736(10)62051-x

    Article  CAS  PubMed  Google Scholar 

  45. Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B (2012) Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev (5):Cd003188. https://doi.org/10.1002/14651858.CD003188.pub3

  46. Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J (2014) Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol 25(Suppl 3):iii124–iii137. https://doi.org/10.1093/annonc/mdu103

    Article  PubMed  Google Scholar 

Download references

Funding

This study was funded by an institutional research grant from Amgen Inc. to and administered by Aarhus University.

Author information

Authors and Affiliations

  1. Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus University, Olof Palmes Allé 43, 8200, Aarhus, Denmark

    Tina Bech Olesen, Ina Trolle Andersen, Anne Gulbech Ording & Vera Ehrenstein

  2. Centre for Observational Research, Amgen Ltd., Uxbridge, England

    Anouchka Seesaghur

  3. Department of Haematology, Herlev Hospital, Copenhagen, Denmark

    Carsten Helleberg

  4. Department of Haematology, Aarhus University Hospital, Aarhus, Denmark

    Trine Silkjær

  5. Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, USA

    Rohini K. Hernandez

  6. Amgen Europe GmbH, Rotkreuz, Switzerland

    Daniela Niepel

  7. Haematology Research Unit, Department of Haematology, Odense University Hospital, Odense, Denmark

    Niels Abildgaard

  8. Department of Clinical Research, University of Southern Denmark, Odense, Denmark

    Niels Abildgaard

Authors
  1. Tina Bech Olesen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ina Trolle Andersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anne Gulbech Ording
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vera Ehrenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anouchka Seesaghur
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Carsten Helleberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Trine Silkjær
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rohini K. Hernandez
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Daniela Niepel
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Niels Abildgaard
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

1. TBO, ITA, AS, VE, and NA conceptualized and designed the study; ITA analyzed the data; all authors contributed to the interpretation of the data.

2. TBO drafted the article; all authors revised the article critically for important intellectual content.

3. All authors approved the final version of the article to be published.

4. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Corresponding author

Correspondence to Tina Bech Olesen.

Ethics declarations

Conflict of interest

TBO, ITA, AGO, TS, and VE are salaried employees of Aarhus University or Aarhus University Hospital. CH is a salaried employee of Herlev Hospital. AS and RKH are employees and stock owners at Amgen. DN is a former employee of Amgen Inc.

Ethics approval

Not required for registry-based studies in Denmark.

Consent to participate

Not required for registry-based studies in Denmark.

Consent for publication

Not required for registry-based studies in Denmark.

Code availability

Contact authors for code requests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

ESM 1

(PDF 195 kb).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Olesen, T.B., Andersen, I.T., Ording, A.G. et al. Use of bisphosphonates in multiple myeloma patients in Denmark, 2005–2015. Support Care Cancer 29, 4501–4511 (2021). https://doi.org/10.1007/s00520-020-05934-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-020-05934-8

Keywords

Search

Navigation